Maria Zannes, who has held the CEO position at the San Antonio-based biotechnology company since 2014, will see a bump in pay ...

Caidya, a clinical research organization (CRO) based in Raleigh, has raised $165 million in private equity to support its growth.

Thus far 2025 has come roaring in as far as large rounds go. Last week more than a dozen companies raised $100 million or ...

Ribometrix, a spinout of UNC-Chapel Hill, has named William Marshall as its new CEO, succeeding former chief executive ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its CEO, Steve ...

CollaMedix, a Cleveland-based medical device company, is poised for growth in 2025 following its recent move to a much larger ...

MLK is the newest addition to the University of Maryland's Biopark set to bring a wave of innovation and opportunity to ...

Financially risky OS Therapies has potential with mid-stage immunotherapy for osteosarcoma, but faces funding challenges and ...

Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder, according to investors ...

Roche's core research spans five large areas. Boris Zaïtra, who now leads corporate business development, is confident his ...